Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test.
Middleton RM, Pearson OR, Ingram G, Craig EM, Rodgers WJ, Downing-Wood H, Hill J, Tuite-Dalton K, Roberts C, Watson L, Ford DV, Nicholas R; UK MS Register Research Group. Middleton RM, et al. J Med Internet Res. 2020 Sep 23;22(9):e18234. doi: 10.2196/18234. J Med Internet Res. 2020. PMID: 32965240 Free PMC article.
OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis.
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N, Scolding N, Rog D, Nicholas R, Marta M, Blain C, Young CA, Ford HL, Matthews PM. Dobson R, et al. Among authors: ford hl. BMJ Open. 2021 Nov 25;11(11):e050176. doi: 10.1136/bmjopen-2021-050176. BMJ Open. 2021. PMID: 34824113 Free PMC article.
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS).
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G, Evangelou N, Ford H, Gallagher P, George K, Geraldes Ramos Dias R, Harman P, Hobart J, King T, Linighan R, MacDougall N, Marta M, Mitchell S, Nicholas R, Rog D, Scalfari A, Scolding N, Webb S, White S, Wilton J, Young C, Matthews PM. Dobson R, et al. Mult Scler Relat Disord. 2022 Jul;63:103894. doi: 10.1016/j.msard.2022.103894. Epub 2022 May 20. Mult Scler Relat Disord. 2022. PMID: 35636271 Free article.
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK.
Jacobs BM, Schalk L, Dunne A, Scalfari A, Nandoskar A, Gran B, Mein CA, Sellers C, Spilker C, Rog D, Visentin E, Bezzina EL, Uzochukwu E, Tallantyre E, Wozniak E, Sacre E, Hassan-Smith G, Ford HL, Harris J, Bradley J, Breedon J, Brooke J, Kreft KL, Tuite Dalton K, George K, Papachatzaki M, O'Malley M, Peter M, Mattoscio M, Rhule N, Evangelou N, Vinod N, Quinn O, Shamji R, Kaimal R, Boulton R, Tanveer R, Middleton R, Murray R, Bellfield R, Hoque S, Patel S, Raj S, Gumus S, Mitchell S, Sawcer S, Arun T, Pogreban T, Brown TL, Begum T, Antoine V, Rashid W, Noyce AJ, Silber E, Morris H, Giovannoni G, Dobson R. Jacobs BM, et al. Among authors: ford hl. BMJ Open. 2023 May 17;13(5):e071656. doi: 10.1136/bmjopen-2023-071656. BMJ Open. 2023. PMID: 37197821 Free PMC article.
Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC, Dobson R, Froud JLJ, St John FA, Anderson VM, Arun T, Buckley L, Evangelou N, Ford HL, Galea I, George S, Gray OM, Hibbert AM, Hu M, Hughes SE, Ingram G, Kalra S, Lim CE, Mathews JTM, McDonnell GV, Mescall N, Norris S, Ramsay SJ, Rice CM, Russell MJ, Shawe-Taylor MJ, Williams TE, Harding KE, Robertson NP. Tallantyre EC, et al. Among authors: ford hl. Eur J Neurol. 2024 Jul;31(7):e16289. doi: 10.1111/ene.16289. Epub 2024 Apr 3. Eur J Neurol. 2024. PMID: 38567516 Free PMC article.
175 results